Autres langues Sanofi

Actions

SAN

FR0000120578

Produits pharmaceutiques

PEA

Marché Fermé - Euronext Paris Autres places de cotation 17:55:00 16/01/2026			Varia. 5j.	Varia. 1 janv.
80,78 ^EUR	-1,04 %		-4,33 %	-2,35 %

16/01	Arch Biopartners Inc. annonce la nomination de Patrick Vink en tant que président du conseil d'administration et le départ à la retraite de Claude Allary du conseil d'administration	CI
16/01	UBS dégrade Sanofi, déplorant l'absence de "pipeline"

Autres langues

16/01	Agomab Therapeutics files for US IPO - SEC filing
16/01	Aktien Europa Schluss: Moderates Minus zum Wochenausklang
16/01	Arch Biopartners Inc. Announces Appointment of Patrick Vink as Chairman of the Board and Retirement of Claude Allary from the Board of Directors
16/01	Europese beurzen doen het rustig aan
15/01	Sector Update: Health Care Stocks Softer Late Afternoon
15/01	Sector Update: Health Care Stocks Softer in Afternoon Trading
15/01	European Stocks Close Mostly Higher in Thursday Trading; GDP Expands in Germany, UK
15/01	Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
15/01	Global markets live: Microsoft, Morgan Stanley, Citigroup, Disney, Spotify…
15/01	Sanofi, Disc Medicine Drug Reviews Delayed as FDA Flags Safety, Efficacy Issues
15/01	Sanofi Gets China Approval for 2 Medicines
15/01	Sicherheitsbedenken bremsen neues Schnellverfahren für Medikamente in den USA
15/01	US FDA delays two drug reviews in new voucher program after safety, efficacy concerns
15/01	Fda pushes back review of Sanofi's diabetes drug Tzield and Disc Medicine's blood disorder drug -documents
15/01	Sanofi Announces Approval of Myqorzo and Redemplo in China
15/01	Morning Meeting: Allentamento e rotazione
15/01	The National Medical Products Administration in China Approves Two Sanofi-Licensed Innovative Medicines for Treatment
15/01	Sanofi Obtains Approvals for Myqorzo, Redemplo in China
15/01	Sanofi: China approves Myqorzo and Redemplo
15/01	Myqorzo and Redemplo approved in China
14/01	Sanofi sees near-term weakness in US vaccines sales due to antivax rhetoric
14/01	Sanofi sees softness in U.S. vaccine demand in near term
14/01	Sanofi CEO says expects flu-COVID combo vaccines in 2027-2028 to drive next surge in vaccine uptake
14/01	Sanofi CEO says current uncertainty makes it a good time for vaccine development, M&A
14/01	Sanofi CEO says expect a slightly softer vaccine uptake rate this year